GVMXXvs its industry peers
A metric-by-metric comparison of GVMXX against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GVMXX본 종목 | — | — | — | — | — | — | — | — | — | — | — | — |
| MDGL | $11.8B#1 | — | 22.4x#1 | 12.3x#1 | 432.1%#1 | 38.1%#2 | -31.3%#2 | -55.0%#2 | -52.5%#2 | — | 48.6%#2 | — |
| TGTX | — | — | — | — | 87.3%#2 | 1811.1%#1 | 20.0%#1 | 74.0%#1 | 14.2%#1 | — | 78.5%#1 | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-08-08.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice